Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States
Open Access
- 6 August 2020
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (2) , 332-343
Abstract
Despite vaccination recommendations, the burden of vaccine-preventable diseases remains high in older adults in the United States (US), contributing to substantial morbidity, mortality, and health care resource use and costs. To adequately plan for health care resource needs and to help inform vaccination policies, burden of disease projections that account for population aging over the coming decades are needed. As a first step, this exploratory study projects the burden of influenza, pertussis, herpes zoster, and pneumococcal disease in adults aged 50 y and older in the US, using a population-based modeling framework with separate decision trees for each vaccine-preventable disease. The model uses projected population estimates from the US Census Bureau to account for changes in the US population over time and then calculates expected numbers of cases and associated costs for each disease, keeping current estimates of age-specific disease incidence, vaccine coverage, and efficacy constant over time. This approach was used to focus the exploratory analysis on the burden of disease that may be expected due to population changes alone, assuming that all else remains unchanged. Due to population growth and the shifting age distribution over the next 30 y, the annual societal economic burden for the four vaccine-preventable diseases is projected to increase from approximately $35 billion to $49 billion, resulting in cumulative costs of approximately $1.3 trillion, as well as more than 1 million disease-related deaths. Given such notable burden, further efforts to increase vaccination coverage and effectiveness in older adults are needed.Keywords
Funding Information
- GlaxoSmithKline Biologicals S.A (HO-17-18466)
This publication has 42 references indexed in Scilit:
- Vaccinated Children and Adolescents With Pertussis Infections Experience Reduced Illness Severity and Duration, Oregon, 2010–2012Clinical Infectious Diseases, 2014
- Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011PLOS ONE, 2013
- Vaccines for preventing pneumococcal infection in adultsCochrane Database of Systematic Reviews, 2013
- Immunosenescence and Novel Vaccination Strategies for the ElderlyFrontiers in Immunology, 2013
- Aging Population and Future Burden of Pneumococcal Pneumonia in the United StatesThe Journal of Infectious Diseases, 2012
- Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide VaccineJAMA, 2012
- A critical literature review of health economic evaluations in pertussis booster vaccinationExpert Review of Pharmacoeconomics & Outcomes Research, 2012
- Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older AdultsJournal of the American Geriatrics Society, 2010
- Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adultsVaccine, 2008
- The Valuation of Human CapitalJournal of Political Economy, 1961